Multi-center safety and efficacy trial evaluating three times per week application of 1% and 5% topical imiquimod for the treatment of genital/perianal warts: L. Edwards, Carolinas Medical Center, Charlotte, NC, USA; A. Ferenczy, Jewish General Hospital, Montreal, Quebec, Canada; L. Eron, Infectious Disease Physicians, Annandale, VA, USA; D. Baker, HSC SUNY, Stony Brook, NY, USA; T. Fox, K. Gayoso, A. Hougham, M. Owens, 3M Pharmaceuticals, St. Paul, MN, USA; and the Topical Imiquimod HPV Study Group